LIVE WEBINAR: Tuesday, December 1, 2020, 5:00 PM – 6:00 PM Eastern Time

Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Oncology

A Multitumor CME/MOC-Accredited Live Webinar Series

Prostate Cancer

Join us on Tuesday, December 1st for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty

Emmanuel S Antonarakis, MD
Professor of Oncology and Urology
Johns Hopkins University
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland


Andrew J Armstrong, MD, ScM
Professor of Medicine, Surgery, Pharmacology and Cancer Biology
Director of Research
Duke Cancer Institute Center for Prostate and Urologic Cancers
Divisions of Medical Oncology and Urology
Duke University
Durham, North Carolina

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Merck, and Sanofi Genzyme.

Tuesday, December 1, 2020
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

MODULE 1: Selection of Therapy for Nonmetastatic Castration-Resistant, Advanced and Metastatic Hormone-Sensitive Prostate Cancer (HSPC)

  • Superior sustained suppression of testosterone with relugolix compared to leuprolide in men with advanced HSPC; potential clinical role of relugolix
  • Key efficacy and safety outcomes observed in the PROSPER, SPARTAN and ARAMIS trials evaluating enzalutamide, apalutamide and darolutamide, respectively, for patients with nonmetastatic castration-resistant prostate cancer (CRPC)
  • FDA approvals of enzalutamide, apalutamide and darolutamide in nonmetastatic CRPC and optimal integration into current clinical algorithms
  • Incidence of adverse events of interest (eg, fatigue, seizures, falls, fractures) observed in patients with nonmetastatic CRPC receiving enzalutamide, apalutamide or darolutamide
  • Clinical, biologic and practical factors guiding the selection of secondary hormonal therapy versus chemotherapy for metastatic HSPC (mHSPC)
  • Long-term efficacy and quality-of-life data with docetaxel or abiraterone and prednisone in combination with androgen deprivation therapy for men with mHSPC
  • Design, entry criteria and key efficacy and safety outcomes from the Phase III trials ARCHES, TITAN and ENZAMET evaluating enzalutamide or apalutamide for mHSPC
  • FDA approvals of enzalutamide and apalutamide for mHSPC; optimal integration into current algorithms
  • Ongoing Phase III evaluation of darolutamide in mHSPC

MODULE 2: Current and Future Management Strategies for Metastatic CRPC (mCRPC)

  • Design, eligibility criteria and key efficacy and safety findings from the CARD trial comparing cabazitaxel to an androgen receptor (AR)-targeted agent for patients with mCRPC and disease progression after docetaxel and an alternative AR-targeted agent; implications for therapeutic sequencing
  • Clinical role and optimal integration of radium-223 into current mCRPC treatment algorithms; available findings with and ongoing studies of radium-223 in combination with other systemic therapies
  • Clinical trial data with the use of olaparib, rucaparib and niraparib for patients with mCRPC who experience disease progression
  • Recent FDA approvals of rucaparib and olaparib for men with mCRPC; implications for genetic testing and routine practice
  • Frequency of PTEN loss in mCRPC; emerging data from the Phase III IPATential150 trial showing improved radiographic progression-free survival with ipatasertib in combination with abiraterone/prednisone in this population
  • Preliminary findings from the mCRPC cohort of the Phase Ib COSMIC-021 trial evaluating cabozantinib in combination with atezolizumab; design and key endpoints of the Phase III CONTACT- 02 trial
  • Other promising investigational strategies for mCRPC (eg, immune checkpoint inhibitors, novel radiopharmaceuticals 

Target Audience
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the published research database supporting the recent FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the discussion of nonresearch treatment options for patients.
  • Recognize the potential side effects of hormonal agents commonly employed in the management of prostate cancer, and develop strategies to prevent, mitigate and manage toxicities.
  • Explore available data with the use of cytotoxic and secondary hormonal therapy for metastatic hormone-sensitive prostate cancer (mHSPC) to design effective treatment plans for patients.
  • Appraise the recent FDA approvals of enzalutamide and apalutamide for patients with mHSPC, and effectively integrate these agents into clinical practice.
  • Assess the available and emerging research surrounding the optimal management of metastatic castration-resistant prostate cancer (mCRPC), and apply recent advances to clinical care.
  • Describe the rationale for testing patients with metastatic prostate cancer for BRCA1/2 or other related mutations, and advise individuals found to harbor these genetic abnormalities about data documenting the efficacy of PARP inhibition in this setting.
  • Evaluate the recent FDA approvals of olaparib and rucaparib for patients with mCRPC, and optimally incorporate these agents into current clinical algorithms.
  • Appreciate emerging Phase III data documenting the efficacy of the novel AKT inhibitor ipatasertib in combination with abiraterone and prednisone/prednisolone in patients with previously untreated mCRPC and functional loss of the tumor-suppressor protein PTEN, and consider the potential role of this strategy.
  • Recall the design of ongoing research studies evaluating other novel agents and strategies for metastatic prostate cancer, and counsel appropriate patients about availability and participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr AntonarakisConsulting Agreements: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Dendreon Pharmaceuticals Inc, ESSA Pharma Inc, GlaxoSmithKline, Janssen Biotech Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Sanofi Genzyme; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Dendreon Pharmaceuticals Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Novartis, Sanofi Genzyme, Tokai Pharmaceuticals Inc; Ownership Interest (Licenser of Patent): QIAGEN. Dr ArmstrongAdvisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Merck; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genomic Health Inc, Janssen Biotech Inc, Merck, Pfizer Inc, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Merck, and Sanofi Genzyme.